20 filings
8-K
VTGN
VistaGen Therapeutics Inc
27 Dec 19
Regulation FD Disclosure
4:05pm
8-K
VTGN
VistaGen Therapeutics Inc
12 Dec 19
U.S. FDA Grants VistaGen Therapeutics Fast Track Designation for PH94B for Treatment of Social Anxiety Disorder
5:14pm
8-K
VTGN
VistaGen Therapeutics Inc
14 Nov 19
VistaGen Reports Topline Phase 2 Results for AV-101 as an Adjunctive Treatment of Major Depressive Disorder
7:46am
8-K
VTGN
VistaGen Therapeutics Inc
8 Nov 19
VistaGen Therapeutics Reports Fiscal 2020 Second Quarter Financial Results and Provides Pipeline Overview
12:00am
8-K
VTGN
VistaGen Therapeutics Inc
30 Oct 19
Other Events
12:00am
8-K
1o9kmgv13t7 8z
9 Oct 19
Regulation FD Disclosure
12:00am
8-K
2d7j2
25 Sep 19
Other Events
4:03pm
8-K
sjq8i4zph5ob9
6 Sep 19
Amendments to Articles of Incorporation or Bylaws
4:55pm
8-K
27x52ib9z7w9am
23 Aug 19
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:37pm
8-K
qk2xpx8e2z8 to4w9u30
16 Aug 19
VistaGen Therapeutics Reports Fiscal 2020 First Quarter Financial Results
12:00am
8-K
0x4vtofjt2hynw9
23 Jul 19
VistaGen Therapeutics Announces USPTO Grant of Patent for Treatment of Depression with Fast-Acting PH10 Neuroactive Nasal Spray
4:31pm
8-K
zk50gj xw
21 Jun 19
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:00pm
8-K
nnc3f
2 May 19
Regulation FD Disclosure
5:22pm
8-K
4s2uciiw5
4 Apr 19
Other Events
4:10pm
8-K
xj0jig95ic023gql vv
14 Mar 19
Regulation FD Disclosure
4:50pm
8-K
mochj8zjx4ji ylflao9
4 Mar 19
Entry into a Material Definitive Agreement
4:15pm
8-K
tzlcf2g loj9yp
19 Feb 19
VistaGen Therapeutics Receives Notice of Allowance for U.S. Patent for Treatment of Depression with PH10
4:18pm
8-K
xswr9kd8p2b8
1 Feb 19
AV-101 Stimulates the Formation of New Brain Cells in Nonclinical Studies
12:00am
8-K
2np2v12by7q eu
15 Jan 19
VistaGen Therapeutics Appoints Pharmaceutical Industry Veteran, Ann Cunningham, to its Board of Directors
4:16pm
8-K
0cllcl6d22pz
11 Jan 19
Regulation FD Disclosure
5:30pm
- Prev
- 1
- Next